keyword
MENU ▼
Read by QxMD icon Read
search

Mikkael Sekeres

keyword
https://www.readbyqxmd.com/read/29757456/cancer-research-in-the-united-states-a-critical-review-of-current-status-and-proposal-for-alternative-models
#1
Hagop M Kantarjian, Ferran Prat, David P Steensma, Razelle Kurzrock, David J Stewart, Mikkael A Sekeres, Joseph Leveque
No abstract text is available yet for this article.
May 14, 2018: Cancer
https://www.readbyqxmd.com/read/29723096/reply-to-a-piccardo-et-al-e-hindi%C3%A3-et-al-m-kreissl-et-al-m-doss-j-buscombe-r-fisher-m-sollini-et-al-m-lichtenstein-and-m-tulchinsky-et-al
#2
Remco J Molenaar, Surbhi Sidana, Tomas Radivoyevitch, Aaron T Gerds, Hetty E Carraway, Matt Kalaycio, Aziz Nazha, David J Adelstein, Christian Nasr, Jaroslaw P Maciejewski, Navneed S Majhail, Mikkael A Sekeres, Sudipto Mukherjee
No abstract text is available yet for this article.
May 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29685952/hypomethylating-agents-in-relapsed-and-refractory-aml-outcomes-and-their-predictors-in-a-large-international-patient-cohort
#3
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphael Itzykson, Ellen K Ritchie, Mikkael A Sekeres, John D Barnard, Nikolai A Podoltsev, Andrew M Brunner, Rami S Komrokji, Vijaya R Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Amir T Fathi, Gail J Roboz, Pierre Fenaux, Mark R Litzow, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Miguel Bergua, Josefina Serrano, Steven D Gore, Amer M Zeidan
Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment-refractory (RR)-AML. Using an international multicenter retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for predictors of response and overall survival (OS). A total of 655 patients from 12 centers received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365 relapsed (56%) patients...
April 24, 2018: Blood Advances
https://www.readbyqxmd.com/read/29667455/beliefs-and-practice-patterns-in-hyperleukocytosis-management-in-acute-myeloid-leukemia-a-large-u-s-web-based-survey
#4
Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, Mark R Litzow, Selina M Luger, Richard M Stone, Harry P Erba, Tae Kon Kim, Mikkael A Sekeres, David P Steensma, Rami S Komrokji, Steven D Gore, Amer M Zeidan
No abstract text is available yet for this article.
April 18, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29661788/germline-tissues-for-optimal-somatic-variant-detection-in-myelodysplastic-syndromes-mds
#5
Eric Padron, Markus C Ball, Jamie K Teer, Jeffrey S Painter, Sean J Yoder, Chaomei Zhang, Ling Zhang, Lynn C Moscinski, Dana E Rollison, Steven D Gore, Rafael Bejar, Matthew J Walter, Mikkael A Sekeres, Rami S Komrokji, Pearlie K Epling-Burnette
No abstract text is available yet for this article.
April 16, 2018: Blood
https://www.readbyqxmd.com/read/29649620/allogeneic-hematopoietic-cell-transplantation-following-the-use-of-hypomethylating-agents-among-patients-with-relapsed-or-refractory-aml-findings-from-an-international-retrospective-study
#6
Maximilian Stahl, Michelle DeVeaux, Pau Montesinos Fernández, Raphaël Itzykson, Ellen K Ritchie, Mikkael A Sekeres, Navneet Majhail, John Barnard, Nikolai A Podoltsev, Andrew Brunner, Rami S Komrokji, Vijaya R Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Gail J Roboz, Pierre Fenaux, Mark Litzow, Amir T Fathi, Sarah Perreault, Tae Kon Kim, Thomas Prebet, Norbert Vey, Vivek Verma, Guido Kobbe, Juan Bergua, Josefina Serrano, Steven D Gore, Amer M Zeidan
No abstract text is available yet for this article.
April 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29618479/comparable-outcomes-of-patients-eligible-versus-ineligible-for-swog-leukemia-studies
#7
Abby Statler, Megan Othus, Harry P Erba, Thomas R Chauncey, Jerald P Radich, Steven Coutre, Anjali Advani, Sucha Nand, Farhad Ravandi, Sudipto Mukherjee, Mikkael A Sekeres
Patients may be deemed ineligible for a clinical trial for reasons that do not directly impact efficacy or safety. We identified and categorized reasons for ineligibility and compared outcomes of ineligible with eligible patients treated on SWOG Leukemia Committee protocols. Patients enrolled in SWOG phase II, II/III, or III protocols open since 2005 were analyzed for eligibility status, reasons for ineligibility, baseline characteristics, Eastern Cooperative Oncology Group (ECOG) performance status (PS), serious adverse events (SAEs), and outcomes, including complete remission (CR) status and overall survival (OS)...
April 4, 2018: Blood
https://www.readbyqxmd.com/read/29572313/strategies-for-success-in-creating-an-effective-multihospital-health-system-pharmacy-and-therapeutics-committee
#8
Mandy C Leonard, Rema Thyagarajan, Amy J Wilson, Mikkael A Sekeres
PURPOSE: Lessons learned from the creation of a multihospital health-system formulary management and pharmacy and therapeutics (P&T) committee are described. SUMMARY: A health system can create and implement a multihospital system formulary and P&T committee to provide evidence-based medications for ideal healthcare. The formulary and P&T process should be multidisciplinary and include adequate representation from system hospitals. The aim of a system formulary and P&T committee is standardization; however, the system should allow flexibility for differences...
April 1, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29470141/denial-s-many-faces
#9
Adrienne R Boissy, Mikkael A Sekeres
No abstract text is available yet for this article.
May 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29416752/fanconi-anemia-germline-variants-as-susceptibility-factors-in-aplastic-anemia-mds-and-aml
#10
Bartlomiej Przychodzen, Hideki Makishima, Mikkael A Sekeres, Suresh Kumar Balasubramanian, Swapna Thota, Bhumika J Patel, Michael Clemente, Cassandra Hirsch, Brittney Dienes, Jaroslaw P Maciejewski
Using next generation sequencing we have systematically analyzed a large cohort of 489 patients with bone marrow failure (BMF), including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), aplastic anemia (AA), and related conditions for the presence of germline (GL) alterations in Fanconi Anemia (FA) and telomerase genes. We have detected an increased frequency of heterozygous FA gene mutations in MDS and to lesser degree in AML suggesting that the presence of one normal allele may not be completely protective and indeed heterozygous FA lesions may have a long latency period before hematologic manifestation...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29396092/long-term-follow-up-for-up-to-5-years-on-the-risk-of-leukaemic-progression-in-thrombocytopenic-patients-with-lower-risk-myelodysplastic-syndromes-treated-with-romiplostim-or-placebo-in-a-randomised-double-blind-trial
#11
Hagop M Kantarjian, Pierre Fenaux, Mikkael A Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Nancy Carpenter, Bhakti Mehta, Janet Franklin, Aristoteles Giagounidis
BACKGROUND: Treatment options for thrombocytopenia in myelodysplastic syndromes are scarce. As described previously in a randomised phase 2 study (n=250), 58 weeks of romiplostim treatment in patients with International Prognostic Scoring System (IPSS)-defined lower-risk (low-risk or intermediate-1 risk) myelodysplastic syndromes led to reduced platelet transfusions (p<0·0001) and increased International Working Group-defined haematological improvement-platelet rates (p<0·0001) versus placebo...
March 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29339439/-idh1-2-mutations-sensitize-acute-myeloid-leukemia-to-parp-inhibition-and-this-is-reversed-by-idh1-2-mutant-inhibitors
#12
Remco J Molenaar, Tomas Radivoyevitch, Yasunobu Nagata, Mohammed Khurshed, Bartolomiej Przychodzen, Hideki Makishima, Mingjiang Xu, Fonnet E Bleeker, Johanna W Wilmink, Hetty E Carraway, Sudipto Mukherjee, Mikkael A Sekeres, Cornelis J F van Noorden, Jaroslaw P Maciejewski
Purpose: Somatic mutations in IDH1/2 occur in approximately 20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2MUT enzymes produce D -2-hydroxyglutarate ( D 2HG), which associates with increased DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in solid tumor cells. Whether this also holds true for IDH1/2 MUT AML is not known. Experimental Design: Well-characterized primary IDH1 MUT , IDH2 MUT , and IDH1/2 WT AML cells were analyzed for DNA damage and responses to daunorubicin, ionizing radiation, and PARP inhibitors...
April 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29331635/sotatercept-with-long-term-extension-for-the-treatment-of-anaemia-in-patients-with-lower-risk-myelodysplastic-syndromes-a-phase-2-dose-ranging-trial
#13
Rami Komrokji, Guillermo Garcia-Manero, Lionel Ades, Thomas Prebet, David P Steensma, Joseph G Jurcic, Mikkael A Sekeres, Jesus Berdeja, Michael R Savona, Odile Beyne-Rauzy, Aspasia Stamatoullas, Amy E DeZern, Jacques Delaunay, Gautam Borthakur, Robert Rifkin, Thomas E Boyd, Abderrhamane Laadem, Bond Vo, Jennie Zhang, Marie Puccio-Pick, Kenneth M Attie, Pierre Fenaux, Alan F List
BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis leading to anaemia. Sotatercept (ACE-011) is a novel activin receptor type IIA fusion protein that acts as a ligand trap to neutralise negative regulators of late-stage erythropoiesis. The aim of the study was to establish a safe and effective dose of sotatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes. METHODS: This open-label, multicentre, dose-ranging, phase 2 trial took place at 11 treatment centres in the USA and France...
February 2018: Lancet Haematology
https://www.readbyqxmd.com/read/29321554/mutations-in-dnmt3a-u2af1-and-ezh2-identify-intermediate-risk-acute-myeloid-leukemia-patients-with-poor-outcome-after-cr1
#14
Caner Saygin, Cassandra Hirsch, Bartlomiej Przychodzen, Mikkael A Sekeres, Betty K Hamilton, Matt Kalaycio, Hetty E Carraway, Aaron T Gerds, Sudipto Mukherjee, Aziz Nazha, Ronald Sobecks, Christopher Goebel, Donna Abounader, Jaroslaw P Maciejewski, Anjali S Advani
Intermediate-risk acute myeloid leukemia (IR-AML) is a clinically heterogeneous disease, for which optimal post-remission therapy is debated. The utility of next-generation sequencing information in decision making for IR-AML has yet to be elucidated. We retrospectively studied 100 IR-AML patients, defined by European Leukemia Net classification, who had mutational information at diagnosis, received intensive chemotherapy and achieved complete remission (CR) at Cleveland Clinic (CC). The Cancer Genome Atlas (TCGA) data were used for validation...
January 10, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29137233/outcome-of-patients-treated-for-myelodysplastic-syndromes-with-5q-deletion-after-failure-of-lenalidomide-therapy
#15
Thomas Prebet, Thomas Cluzeau, Sophie Park, Mikkael A Sekeres, Ulrich Germing, Lionel Ades, Uwe Platzbecker, Katharina Gotze, Norbert Vey, Esther Oliva, Mary M Sugrue, Cecile Bally, Charikleia Kelaidi, Najla Al Ali, Pierre Fenaux, Steven D Gore, Rami Komrokji
While lenalidomide (LEN) is the standard of care for the lower-risk myelodysplastic syndromes (MDS) patients with deletion 5q, 35% will not respond to or do not tolerate the drug. Moreover, most of the patients will lose their response after a few years. Defining the outcome of patients with LEN failure and determining the impact of subsequent therapies is therefore important to develop alternative strategies. Based on an international collaboration, we were able to compile a total of 392 patient cases of lower-risk MDS patients with 5q deletion and to analyze their outcome after failure of lenalidomide...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29112938/impact-of-baseline-cytogenetic-findings-and-cytogenetic-response-on-outcome-of-high-risk-myelodysplastic-syndromes-and-low-blast-count-aml-treated-with-azacitidine
#16
Marie Sébert, Rami S Komrokji, Mikkael A Sekeres, Thomas Prebet, Thomas Cluzeau, Valeria Santini, Emmanuel Gyan, Alessandro Sanna, Najla HAl Ali, Sean Hobson, Virginie Eclache, Alan List, Pierre Fenaux, Lionel Adès
Karyotype according to the revised IPSS is a strong independent prognostic factor for overall survival (OS) in myelodysplastic syndromes (MDS), however established in untreated patients. The prognostic impact of cytogenetics and cytogenetic response (CyR) in MDS patients receiving azacitidine (AZA) remains uncertain. We examined the prognostic value of baseline cytogenetics and CyR for overall response rate (ORR) and OS in 702 AZA-treated higher risk MDS and low blast count acute myeloid leukemia (AML), including 493 (70%) with abnormal karyotype...
December 2017: Leukemia Research
https://www.readbyqxmd.com/read/28958288/optimizing-the-use-of-hypomethylating-agents-in-myelodysplastic-syndromes-selecting-the-candidate-predicting-the-response-and-enhancing-the-activity
#17
REVIEW
Yazan Madanat, Mikkael A Sekeres
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have a substantial impact on patients' quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection and identify the right timing of HMA treatment initiation and response evaluation to maximize patient benefit...
July 2017: Seminars in Hematology
https://www.readbyqxmd.com/read/28893734/origins-of-myelodysplastic-syndromes-after-aplastic-anemia
#18
MULTICENTER STUDY
Eiju Negoro, Yasunobu Nagata, Michael J Clemente, Naoko Hosono, Wenyi Shen, Aziz Nazha, Tetsuichi Yoshizato, Cassandra Hirsch, Bartlomiej Przychodzen, Reda Z Mahfouz, Teodora Kuzmanovic, Mikkael A Sekeres, Hideki Makishima, Seishi Ogawa, Jaroslaw P Maciejewski
No abstract text is available yet for this article.
October 26, 2017: Blood
https://www.readbyqxmd.com/read/28880971/development-and-validation-of-a-novel-acute-myeloid-leukemia-composite-model-to-estimate-risks-of-mortality
#19
Mohamed L Sorror, Barry E Storer, Amir T Fathi, Aaron T Gerds, Bruno C Medeiros, Paul Shami, Andrew M Brunner, Mikkael A Sekeres, Sudipto Mukherjee, Esteban Peña, Mahmoud Elsawy, Shylo Wardyn, Jennifer Whitten, Rachelle Moore, Pamela S Becker, Jeannine S McCune, Frederick R Appelbaum, Elihu H Estey
Importance: To our knowledge, this multicenter analysis is the first to test and validate (1) the prognostic impact of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia (AML) and (2) a novel, risk-stratifying composite model incorporating comorbidities, age, and cytogenetic and molecular risks. Objective: To accurately estimate risks of mortality by developing and validating a composite model that combines the most significant patient-specific and AML-specific features...
December 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28774880/randomized-phase-2-study-of-low-dose-decitabine-vs-low-dose-azacitidine-in-lower-risk-mds-and-mds-mpn
#20
RANDOMIZED CONTROLLED TRIAL
Elias Jabbour, Nicholas J Short, Guillermo Montalban-Bravo, Xuelin Huang, Carlos Bueso-Ramos, Wei Qiao, Hui Yang, Chong Zhao, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Koji Sasaki, Zeev Estrov, Jorge Cortes, Farhad Ravandi, Yesid Alvarado, Rami Komrokji, Mikkael A Sekeres, David P Steensma, Amy DeZern, Gail Roboz, Hagop Kantarjian, Guillermo Garcia-Manero
Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle...
September 28, 2017: Blood
keyword
keyword
114088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"